Financials data is unavailable for this security.
View more
Year on year BioNexus Gene Lab Corp 's revenues fell -10.60% from 10.93m to 9.77m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 355.97k to a larger loss of 2.63m.
Gross margin | 13.88% |
---|---|
Net profit margin | -24.02% |
Operating margin | -22.96% |
Return on assets | -23.17% |
---|---|
Return on equity | -28.44% |
Return on investment | -27.98% |
More ▼
Cash flow in USDView more
In 2023, BioNexus Gene Lab Corp increased its cash reserves by 179.84%, or 3.81m. Cash Flow from Financing totalled 5.75m or 58.89% of revenues. In addition the company used 1.30m for operations while cash used for investing totalled 382.58k.
Cash flow per share | -0.1343 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.5403 |
---|---|
Tangible book value per share | 0.5403 |
More ▼
Balance sheet in USDView more
Current ratio | 5.60 |
---|---|
Quick ratio | 4.87 |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼